Sector
snapshot - Future of #FunctionalMushrooms and #PsychedelicMushrooms (OTC:
$LRSV) (OTCQB: $SHRMF) (OTCQB: $MMEDF) (OTC: $RVVTF); @res_pet @mindmedco @Revive_RVV
Point Roberts WA, Delta BC – February 23, 2021 - Investorideas.com, a leading investor news resource on health and wellness stocks releases a sector snapshot looking at a health revolution taking place with the growing functional mushroom and psychedelic mushroom markets, featuring Link Reservations Inc. (OTC PINK: LRSV).
Read this news,
featuring LRSV in full at https://www.investorideas.com/news/2021/lohas/02231LRSV-SHRMF-MMEDF-RVVTF.asp
According
to Data Bridge Market
Research, “The functional mushroom market is expected to gain
market growth in the forecast period of 2021 to 2028. Data Bridge Market
Research analyses that the market is growing with the CAGR of 7.22% in the
forecast period of 2021 to 2028 and is expected to reach USD 555.94 billion by
2028. The increasing use of the ingredient in the healthcare sector is escalating
the growth of functional mushroom market.”
New to the functional mushroom market, Link
Reservations Inc. (OTC PINK: LRSV), a provider of wellness and cannabidiol
(CBD) products for both humans and pets just announced the expansion
of its DailyLifeCBD product line to include a suite of functional
mushroom-infused products. The Company, having recently acquired DailyLifeCBD to enter the
health and wellness sector, is looking to expand its range of complementary
well-being products with an emphasis on natural and organic ingredients.
Due to the Covid-19 global pandemic, consumers are
increasingly searching for ways to boost their immune system, seen by the
market growth of alternative and complementary products. Functional (or
medicinal) mushrooms possess beneficial properties such as antibacterial,
anti-inflammatory and immunomodulating effects - meaning they help keep the
immune system in balance. Functional mushrooms are specific varieties, such as
Shiitake, Reishi, Maitake and Chaga, amongst others.
Having recently expanded into the health and
wellness sector through its acquisition of DailyLifeCBD - a website
selling CBD products for people - LRSV is now pursuing the development and
commercialization of rapid onset treatments capable of improving health outcomes
such as depression and post-traumatic stress disorder (PTSD), as well as
substance and alcohol use disorders.
"We are very excited and much looking forward
to the opportunity for growth brought by the sale and distribution of our new
premium, functional mushroom-infused suite of products. As a Company, our focus
continues to be on providing high quality, natural products that can benefit
the health and wellbeing of consumers," commented Rene Lauritsen, CEO at
Link Reservations Inc. "At the same time we aim to continue growing our
revenue and increasing shareholder value through acquisitions and product range
expansion. The LRSV team is confident of the potential that this new product
suite has in enhancing the health and wellness of millions of consumers," he
added.
The Company plans to initiate activities through
DailyLifeCBD with a range of non-edible lifestyle products for people and
expand on the range as the site and demand grows. LRSV is considering the
possibility of a subsidiary solely focused on its mushroom-infused products.
"Our expectation, based on discussions with
our manufacturer is to have these new products available for sale in the coming
weeks - we are very excited by this. We will keep shareholders and the
investment community updated through press releases as developments arise,"
said Lauritsen.
Finally, if and when Federal and jurisdiction laws
allow, Link Reservations Inc. (OTC PINK: LRSV) is setting its eyes on a greater prize, with a
potential suite of psychedelic mushroom-infused products to follow the
functional mushroom products.
The
Psychedelic mushroom stock sector has grown enough that an ETF has been created
around it, currently trading on the NEO Exchange, the HORIZONS PSYCHEDELIC STOCK INDEX ETF is an
indication of future growth opportunities.
TOP
10 HOLDINGS AS AT FEBRUARY 12, 2021:
Security Name Weight
SEELOS THERAPEUTICS
INC 12.51%
NUMINUS WELLNESS INC 10.09%
FIELD TRIP HEALTH
LTD 9.99%
MIND MEDICINE
(MINDMED) INC SUB VTG 9.49%
COMPASS PATHWAYS
PLC ADR 8.71%
RED LIGHT HOLLAND
CORP 6.9%
GREENBROOK TMS INC
NEW 6.82%
CYBIN INC 6.24%
REVIVE THERAPEUTICS
LTD. 5.14%
JOHNSON &
JOHNSON 4%
Last week, Revive Therapeutics Ltd.
(CSE: RVV) ( RVVTF), a
specialty life sciences company focused on the research and development of
therapeutics for medical needs and rare disorders and one of the holdings in
the ETF announced that,
further to its press release dated December 21, 2020, it has entered into an
asset purchase agreement with Newscope Capital Corporation (CSE: PHRM) (OTCQB:
PHRRF) to acquire the full rights to PharmaTher Inc.’s intellectual property (the “Acquired Assets”)
pertaining to psilocybin (the “Acquisition”). PharmaTher, a wholly-owned
subsidiary of Newscope, is a specialty life sciences company focused on the
research and development of psychedelic pharmaceuticals.
“With this acquisition, we have
solidified our foundation in having a leading psychedelics pharmaceutical
platform with a focus on proprietary psilocybin-based therapeutics that
includes the development of an oral thin film product in collaboration with the
University of Wisconsin-Madison, a novel biosynthetic version of psilocybin
based on a natural biosynthesis enzymatic platform developed by Dr. Gavin
Williams, Professor and Researcher at North Carolina State University, a
clinical study with the University of Wisconsin evaluating psilocybin in the
treatment of methamphetamine use disorder, and PharmaTher’s psilocybin research
initiatives and intellectual property in stroke, traumatic brain injury, cancer
and drug combinations,” said Michael Frank, CEO of Revive. “We are now in a
position to advance our psilocybin program for future clinical development in
various unmet clinical needs in mental health, cancer and neurological
disorders.”
Looking at how psychedelic mushrooms
may be playing a role in mental health, in late January Champignon Brands Inc.
(OTCQB: SHRMF)
Chairman and CEO, Roger McIntyre announced the
opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic
in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics
(CRTCE Clinics) in addressing the unmet need of depression and suicide through
novel ketamine therapy treatment.
“Over twenty clinical trials have
demonstrated that ketamine and esketamine have rapid and robust antidepressant
effects in patients that have failed to respond to conventional
antidepressants. During the COVID-19 pandemic, the need for effective treatment
has become exponentially critical," said Dr. Joshua Rosenblat, Medical
Director, CRTCE. "Ketamine treatment for depression is very difficult to
access in Canada. This third clinic should allow more people to access treatment."
MindMed (NEO:MMED) (OTCQB:MMEDF), a
psychedelic medicine biotech company that discovers, develops and deploys
psychedelic inspired medicines and therapies to address addiction and mental
illness announced just
recently that it will acquire HealthMode, a digital medicine and
therapeutics startup that uses Artificial Intelligence (AI)-enabled digital
measurement to increase the precision and speed of clinical research and
patient monitoring.
MindMed Co-Founder and CEO, J.R.
Rahn said, "Our mission is to make MindMed as much a digital medicine
company as a drug development company. With the addition of Dan and Bradford's
team of engineers and product experts, our digital medicine division, Albert,
is now the Special Ops of digital medicine, applying machine learning to drug
development and patient care. The future of modern mental healthcare and
psychedelic medicine ultimately will rely on improving infrequent,
self-reported and observed measures for mental health to a paradigm where the
continual digital measurement of our mind and body is as vital as the drug
treatment itself. In effect, we see a future mental health treatment paradigm
where potential drug products such as our LSD experiential therapy might be
prescribed right alongside software application programming interfaces (APIs)
to prepare the patient for treatment and optimally monitor the after-care of
one's anxiety disorder."
What does the future hold for
functional and psychedelic mushrooms for consumers and investors? According to a recent article,”After
successfully traveling through the niche wellness-to-mainstream pipeline,
mushrooms are set to get more “magical” with the prospect of wider legalization
of psychedelics.”
Investors can research the sector
with a list of health and wellness
stocks at
Investorideas.com
Investors can research psychedelic
stocks at https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp
About
Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third
party news, research and original financial content. Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining,
sports biotech, water, renewable energy and more. Investor Idea’s original
branded content includes the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move
podcast and column, Cleantech
and Climate Change , Exploring
Mining
the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. Disclosure: this news article featuring LRSV
is a paid for news release on Investorideas.com – third party: Learn more about
the cost of publishing your news release and our article creation https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact
Investorideas.com
800-665-0411
